Amiloride Treatment in Multiple Sclerosis

INTERVENTION: Trade Name: Amiloride Product Name: Amiloride Hydrochloride Pharmaceutical Form: Coated tablet CONDITION: Multiple Sclerosis PRIMARY OUTCOME: Main Objective: The prinicipal aim of this study is to assess the efficacy of Amiloride on neurodegenerative change in multiple sclerosis.The primary outcome measure will be change in Magnetic resonance imaging markers studied over a period of 12 months. Primary end point(s): MRI evidence of slowing of progression. However the study will terminate at 52 weeks after patients have been started on study drug Secondary Objective: The secondary research objective will be to assess Physician based EDSS and patient based MSIS‐29. The overall mean change from baseline to end of study will be assessed. INCLUSION CRITERIA: 1. Subjects with primary progressive MS, who have completed the Phase I of the study which was performed over 52 weeks, when patients were not given any specific treatment. 2. Willing and able to comply with study visits according to protocol for the full study period Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) F.1.3.1 Number of subjects for this age range